Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate …
E Giovannetti, C Lemos, C Tekle, K Smid… - Molecular …, 2008 - ASPET
Because the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib and
the multitargeted antifolate pemetrexed are registered in the treatment of second-line non …
the multitargeted antifolate pemetrexed are registered in the treatment of second-line non …
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate …
E Giovannetti, C Lemos, C Tekle, K Smid… - Molecular …, 2008 - europepmc.org
Because the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib and
the multitargeted antifolate pemetrexed are registered in the treatment of second-line non …
the multitargeted antifolate pemetrexed are registered in the treatment of second-line non …
[引用][C] Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with the …
E Giovannetti, C Lemos, C Tekle, K Smid… - Molecular …, 2008 - ASPET
Since the EGFR tyrosine-kinase inhibitor erlotinib and the multitargeted antifolate
pemetrexed are registered in the treatment of second-line non-small-cell lung cancer …
pemetrexed are registered in the treatment of second-line non-small-cell lung cancer …
[引用][C] Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted …
E GIOVANNETTI - Mol Pharmacol, 2008 - cir.nii.ac.jp
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth
factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in …
factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in …
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate …
E Giovannetti, C Lemos, C Tekle… - Molecular …, 2008 - pubmed.ncbi.nlm.nih.gov
Because the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib and
the multitargeted antifolate pemetrexed are registered in the treatment of second-line non …
the multitargeted antifolate pemetrexed are registered in the treatment of second-line non …
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate …
E Giovannetti, C Lemos, C Tekle, K Smid… - MOLECULAR …, 2008 - arpi.unipi.it
Because the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib and
the multitargeted antifolate pemetrexed are registered in the treatment of second-line non …
the multitargeted antifolate pemetrexed are registered in the treatment of second-line non …
[PDF][PDF] Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with the …
E Giovannetti, C Lemos, C Tekle, K Smid, S Nannizzi… - 2008 - Citeseer
Since the EGFR tyrosine-kinase inhibitor erlotinib and the multitargeted antifolate
pemetrexed are registered in the treatment of second-line non-small-cell lung cancer …
pemetrexed are registered in the treatment of second-line non-small-cell lung cancer …
[引用][C] Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted …
E Giovannetti, C Lemos… - Molecular …, 2008 - researchinformation.amsterdamumc …
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal
growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed …
growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed …
[PDF][PDF] Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with the …
E Giovannetti, C Lemos, C Tekle, K Smid, S Nannizzi… - 2008 - academia.edu
Since the EGFR tyrosine-kinase inhibitor erlotinib and the multitargeted antifolate
pemetrexed are registered in the treatment of second-line non-small-cell lung cancer …
pemetrexed are registered in the treatment of second-line non-small-cell lung cancer …
[PDF][PDF] Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with the …
E Giovannetti, C Lemos, C Tekle, K Smid, S Nannizzi… - 2008 - academia.edu
Since the EGFR tyrosine-kinase inhibitor erlotinib and the multitargeted antifolate
pemetrexed are registered in the treatment of second-line non-small-cell lung cancer …
pemetrexed are registered in the treatment of second-line non-small-cell lung cancer …